[go: up one dir, main page]

US3920834A - Light-screening compositions and method - Google Patents

Light-screening compositions and method Download PDF

Info

Publication number
US3920834A
US3920834A US396278A US39627873A US3920834A US 3920834 A US3920834 A US 3920834A US 396278 A US396278 A US 396278A US 39627873 A US39627873 A US 39627873A US 3920834 A US3920834 A US 3920834A
Authority
US
United States
Prior art keywords
canthaxanthin
apo
mixture containing
component
carotenal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US396278A
Inventor
Heinrich Klaui
Wilheim Friedrich Korner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH1048170A external-priority patent/CH552388A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to US396278A priority Critical patent/US3920834A/en
Application granted granted Critical
Publication of US3920834A publication Critical patent/US3920834A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures

Definitions

  • ABSTRACT Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.
  • a sun screen agent as hereinafter defined can be administered internally and can be stored in sufficient amounts in the skin to bring about an effect similar to the filtering effect of conventional externally applied sun screen agents.
  • the internal administration of canthaxanthin in combination with other carotenoids has the desired effect. It has been found that when canthaxanthin is administered orally in combination with other carotenoids, it, as well as the other carotenoids, will become stored in the skin and prophylactically protect against sun erythema and sunburn and reduce photosenitivity.
  • canthaxanthin alone protects against sunburn, sun erythema and reduces photosensitivity, it imparts an undesirable reddish color to the skin, it can, however, be used successfully in combination with other carotenoids which are capable of being stored in the skin and which filter ultraviolet light rays in the 290-310 nm. range.
  • carotenoids which are suitable for use in oral sun screen compositions in combination with canthaxanthin are B-carotene, B- apo-8'-carotenal, B-apo-8'-carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin, echinenone, citranaxanthin, torularhodin aldehyde, apo-4--,B-carotenal, C dialdehyde, lycopene, capsanthin, rhodoxanthin and astaxanthin.
  • the most preferred compounds of the above group for combination with canthaxanthin in sun screen compositions according to this invention are B-carotene, ,B-apo-8'-carotenal and B-apo-8-carotenoic acid ethyl ester. Of the remaining carotenoids which are suitable, bixin, zeaxanthin and crocetin are preferred.
  • compositions containing the active ingredients are administered internally in any convenient dosage 2 form, preferably in the form of capsules.
  • the oral ad-. ministration forms which are suitable, e.g., capsules, can contain various amounts of active ingredients, however, a total amount of from about 5 mg. to about 50 mg. of active ingredients, are generally used.
  • the oral unit dosage form contains from about 10 mg. to about 30 mg. of active ingreclients.
  • the active ingredients are generally administered orally on a daily basis.
  • the daily dosage amounts are usually from about 5 mg. to about 100 mg. of active ingredients administered in one or more doses throughout the day. It ispreferable to administer about 50 mg. to about 100 mg. and particularly about mg. of active ingredients daily.
  • the dosages and dosage regimen described relate to adults.
  • the dosage for children is generally about one-half the dosage for adults administered in a similar daily regimen.
  • the active combination should preferably contain at least about 50% by weight of canthaxanthin with the upper limit restricted only by the reddish color imparted to the skin. Preferably up to about 75 canthaxanthin is used in the combination.
  • the remainder of the active combination in the oral dosage form e.g., from about 25 to 50 by weight is a carotenoid or mixtures thereof as listed above.
  • the oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms.
  • edible, non-toxic pharmaceutically acceptable stabilizers such as the tocopherol compounds usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
  • water-soluble signifies water-soluble preparations which contain 10% by weight of the corresponding carotenoid.
  • Cunthuxanthin water-soluble 100 mg.
  • B-curotene I071; watersoluhle 100 mg.
  • Mannitol 60 mg.
  • Canthaxanthin (10%; water-soluble) 100 mg.
  • B-carotene (10%: water-soluble) 100 mg.
  • DL-a-Tocopheryl acetate 20 mg.
  • Ascorbic acid 40 mg.
  • compositions prepared according to this example equal weights of either B-apo-8-carotenal, B-apo- 8-carotenoic acid ethyl ester or citranaxanthin can be used in the place of ,B-carotene.
  • a method for the prophylactic treatment of sun erythema, sunburn and photosensiti'vity caused by ultraviolet light rays which comprises orally administering to a person in need of such treatment an oral composition comprising a. pharmaceutically acceptable carriers and excipients or mixtures thereof, and
  • a carotenoid selected from the group consisting of ,B-carotene, B-apo-8'-carotenal, B-apo-8+ carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin and citranaxanthin
  • component (b) is a mixture containing canthaxanthin and B-carotene.
  • component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenal.
  • component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenoic acid ethyl ester.
  • component (b) is a mixture containing canthaxanthin and citranaxanthin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.

Description

United States Patent [191 Kl'ziui et a1.
[ Nov. 18, 1975 LIGHT-SCREENING COMPOSITIONS AND METHOD [75] Inventors: Heinrich Kliiui, Riehen; Wilheim Friedrich Kiir'ner, Bettingen, both of Switzerland [73] Assignee: Hoffmann-La Roche Inc., Nutley,
[22] Filed: Sept. 11, 1973 [21] Appl. No.: 396,278
Related US. Application Data [63] Continuation-in-part of Ser. No. 153,118, June 14,
1971, abandoned.
[30] Foreign Application Priority Data July 10, 1970 Switzerland 10481/70 [56] References Cited UNITED STATES PATENTS 3,252,864 5/1966 Klaui 424/331 3,252,865 5/1966 Klaui 424/331 FOREIGN PATENTS OR APPLICATIONS 2,129,653 1/1972 Germany OTHER PUBLICATIONS British Journal of Dermatology, Vol. 77, Dec. 1965, pp. 622-626.
J. of Invest. Derm, Vol. 32, Jan-June 1959, pp,
Chemical Abstracts, Vol. 65:10423b, Referring to Belg. Patent 670,243 and Vol. 63:1106g to egg yolk.
Primary Examiner-Donald B. Meyer J Attorney, Agent, or FirmSamuel L. Welt; Jon S. Saxe; Gerald S. Rosen [57] ABSTRACT Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.
5 Claims, No Drawings I LIGHT-SCREENING COMPOSITIONS AND METHOD RELATED APPLICATIONS This application is a continuation-in-part of US. patent application Ser. No. 153,118, filed June 14, 1971 now abandoned, the benefit of the priority date of which is hereby claimed.
BACKGROUND or THE INVENTION Prolonged exposure to the sun, particularly in lightskinned persons, generally leads to an initial redness of the skin which becomes brown after a period of time. This redness is generally painful and can result in the skin peeling. The damage to the skin is caused by the ultraviolet portion of sunlight in the range of about 290-310 nm. Many attempts have been made to filter ofi the damaging ultraviolet wave lengths from the skin with externally applied sun screen agents. These. sun screen agents are generally satisfactory while. they are on the skin. They are glisadvantageoussince they do not remain on the skin for a sufficiently'long time to be adequately effective and as a consequence have to be repeatedly reapplied at frequent intervals. Furthermore, many of the external sun screen agents are rather greasy and uncomfortable to the user.
There is thus a need for an effective sun screen agen which is efficacious upon prolonged use and which is facily administered.
DETAILED DESCRIPTION OF THE INVENTION It has been found according to this invention that a sun screen agent as hereinafter defined can be administered internally and can be stored in sufficient amounts in the skin to bring about an effect similar to the filtering effect of conventional externally applied sun screen agents. According to this invention, it has been found that the internal administration of canthaxanthin in combination with other carotenoids has the desired effect. It has been found that when canthaxanthin is administered orally in combination with other carotenoids, it, as well as the other carotenoids, will become stored in the skin and prophylactically protect against sun erythema and sunburn and reduce photosenitivity.
While the use of canthaxanthin alone protects against sunburn, sun erythema and reduces photosensitivity, it imparts an undesirable reddish color to the skin, it can, however, be used successfully in combination with other carotenoids which are capable of being stored in the skin and which filter ultraviolet light rays in the 290-310 nm. range. Among those carotenoids which are suitable for use in oral sun screen compositions in combination with canthaxanthin are B-carotene, B- apo-8'-carotenal, B-apo-8'-carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin, echinenone, citranaxanthin, torularhodin aldehyde, apo-4--,B-carotenal, C dialdehyde, lycopene, capsanthin, rhodoxanthin and astaxanthin.
The most preferred compounds of the above group for combination with canthaxanthin in sun screen compositions according to this invention, are B-carotene, ,B-apo-8'-carotenal and B-apo-8-carotenoic acid ethyl ester. Of the remaining carotenoids which are suitable, bixin, zeaxanthin and crocetin are preferred.
The compositions containing the active ingredients are administered internally in any convenient dosage 2 form, preferably in the form of capsules. The oral ad-. ministration forms which are suitable, e.g., capsules, can contain various amounts of active ingredients, however, a total amount of from about 5 mg. to about 50 mg. of active ingredients, are generally used.
Preferably, however, the oral unit dosage form contains from about 10 mg. to about 30 mg. of active ingreclients. The active ingredients are generally administered orally on a daily basis. The daily dosage amounts are usually from about 5 mg. to about 100 mg. of active ingredients administered in one or more doses throughout the day. It ispreferable to administer about 50 mg. to about 100 mg. and particularly about mg. of active ingredients daily. The dosages and dosage regimen described relate to adults. The dosage for children is generally about one-half the dosage for adults administered in a similar daily regimen.
In order to insure the prophylactic effect against sun erythema, sunburn and reduction of photosensitivity is effected and in order to insure that sufficient active ingredients have been stored in the tissues of the skin, it is necessary to treat the patient in the manner described continuously during the period of about 10 to 20 days before expected exposure to the sun. Tests on light skinned persons conducted according to. the method of Wucherpfennig [Strahlentherapie Vol. 40, page 201 (1931)] have shown that the prophylactic use of the sun screen compositions of this invention produce a significant protective effect against ultraviolet rays and particularly protect against and delay the formation of erythema caused by the ultraviolet rays. Finally, prophylactic administration of the compositions of this invention to persons who are in general strong risks for sunburn, such as those exposed to strong sunlight in high elevations or on lakes, indicates the treatment is successful since such persons exhibited no sun erythema or sunburn.
When the combination preparations of canthaxanthin and one or more of the carotenoids listed are used, then the active combination should preferably contain at least about 50% by weight of canthaxanthin with the upper limit restricted only by the reddish color imparted to the skin. Preferably up to about 75 canthaxanthin is used in the combination. The remainder of the active combination in the oral dosage form, e.g., from about 25 to 50 by weight is a carotenoid or mixtures thereof as listed above. The oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms. Additionally, edible, non-toxic pharmaceutically acceptable stabilizers such as the tocopherol compounds usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
In the following examples which illustrate the invention the expression 10%; water-soluble signifies water-soluble preparations which contain 10% by weight of the corresponding carotenoid.
EXAMPLE 1 Capsules of the following composition are manufactured in a conventional manner:
Cunthuxanthin water-soluble) 100 mg. B-curotene I071; watersoluhle) 100 mg. Mannitol 60 mg. Talcum 8 mg.
EXAMPLE 2 Capsules of the following composition are manufactured in a conventional manner:
Canthaxanthin (10%; water-soluble) 100 mg. B-carotene (10%: water-soluble) 100 mg. DL-a-Tocopheryl acetate 20 mg. Ascorbic acid 40 mg. Mannitol 90 mg. Talcum 12 mg.
In the compositions prepared according to this example, equal weights of either B-apo-8-carotenal, B-apo- 8-carotenoic acid ethyl ester or citranaxanthin can be used in the place of ,B-carotene.
We claim:
1. A method for the prophylactic treatment of sun erythema, sunburn and photosensiti'vity caused by ultraviolet light rays which comprises orally administering to a person in need of such treatment an oral composition comprising a. pharmaceutically acceptable carriers and excipients or mixtures thereof, and
b. from about 5 mg. to about 50 mg. of a mixture containing from about 50% to by weight of canthaxanthin and from about 25% to 50% by weight of a carotenoid selected from the group consisting of ,B-carotene, B-apo-8'-carotenal, B-apo-8+ carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin and citranaxanthin, for a period of from about 10 to about 20 days prior to expected exposure to sunlight.
2. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-carotene.
3. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenal.
4. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenoic acid ethyl ester.
5. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and citranaxanthin.

Claims (5)

1. A METHOD FOR THE PROPHYLACTIC TREATMENT OF SUN ERYTHEMA, SUNBURN AND PHOTOSENSITIVITY CAUSED BY ULTRAVIOLET LIGHT RAYS WHICH COMPRISES ORALLY ADMINISTERING TO A PERSON IN NEED OF SUCH TREATMENT AN ORAL COMPOSITION COMPRISING A. PHARMACEUTICALLY ACCEPTABLE CARRIERS AND EXCIPIENTS OR MIXTURES THEREOF, AND B. FROM ABOUT 5 MG. TO ABOUT 50MG. OF A MIXTURE CONTAINING FROM ABOUT 50% TO 75% BY WEIGHT OF CANTHAXANTHIN AND FROM ABOUT 25% TO 50% BY WEIGHT OF A CAROTENOID SELECTED FROM THE GROUP CONSISTING OF B-CAROTENE, B-APO-8''CAROTENAL, B-APO-8''-CAROTENIC ACID ETHYL ESTER, BIXIN, ZEAXANTHIN, CROCETIN AND CITRANAXANTHIN, FOR A PERIOD OF FROM ABOUT 10 TO ABOUT 20 DAYS PRIOR TO EXPECTED EXPOSURE TO SUNLIGHT.
2. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -carotene.
3. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -apo-8''-carotenal.
4. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -apo-8''-carotenoic acid ethyl ester.
5. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and citranaxanthin.
US396278A 1970-07-10 1973-09-11 Light-screening compositions and method Expired - Lifetime US3920834A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US396278A US3920834A (en) 1970-07-10 1973-09-11 Light-screening compositions and method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1048170A CH552388A (en) 1970-07-10 1970-07-10 LIGHT PROTECTION AGENTS.
US15311871A 1971-06-14 1971-06-14
US396278A US3920834A (en) 1970-07-10 1973-09-11 Light-screening compositions and method

Publications (1)

Publication Number Publication Date
US3920834A true US3920834A (en) 1975-11-18

Family

ID=27176441

Family Applications (1)

Application Number Title Priority Date Filing Date
US396278A Expired - Lifetime US3920834A (en) 1970-07-10 1973-09-11 Light-screening compositions and method

Country Status (1)

Country Link
US (1) US3920834A (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
US4190594A (en) * 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4713398A (en) * 1985-08-30 1987-12-15 Microbio Resources, Inc. Naturally-derived carotene/oil composition
WO1991003571A1 (en) * 1989-08-30 1991-03-21 Applied Food Biotechnology, Inc. Production of zeaxanthin and zeaxanthin-containing compositions
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
US5510551A (en) * 1991-04-12 1996-04-23 Humanetics Corporation Extraction of carotenoids from natural sources
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
WO1996019217A1 (en) * 1994-12-22 1996-06-27 Henkel Corporation Pharmaceutical compositions comprising lycopene
EP0759294A2 (en) * 1995-06-15 1997-02-26 Mutsunori Fujiwara Hypercholesterolemia therapeutic agent
US5712311A (en) * 1995-06-16 1998-01-27 L'oreal Cosmetic or dermatological composition with controlled release of active principle containing a photoconvertible carotenoid
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
US6433025B1 (en) * 2000-04-13 2002-08-13 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
US20030078304A1 (en) * 2000-03-27 2003-04-24 Tove Andersson Method of inhibiting the expression of inflammatory cytokines and chemokines
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US20030108598A1 (en) * 2000-10-27 2003-06-12 Garnett Kevin M. Zeaxanthin formulations for human ingestion
WO2003047528A2 (en) * 2001-12-04 2003-06-12 Levy Pedro E Supplements containing annatto extracts and carotenoids and methods for using the same
WO2003070260A1 (en) * 2002-02-21 2003-08-28 Societe Des Produits Nestle S.A. A photoprotective orally administrable composition for skin
US20040081628A1 (en) * 2002-10-28 2004-04-29 Gierhart Dennis L. Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US6787147B1 (en) * 1998-10-23 2004-09-07 Norman Huner Solar radiation protection composition
US20050053559A1 (en) * 2001-11-14 2005-03-10 Morris Zelkha Carotenoid composition and method for protecting skin
US20050069505A1 (en) * 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
US20050147648A1 (en) * 2003-03-10 2005-07-07 Gierhart Dennis L. Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20050171212A1 (en) * 2003-11-17 2005-08-04 Gierhart Dennis L. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US20090104169A1 (en) * 2002-02-21 2009-04-23 Nestec S. A. Pet food composition for skin photoprotection
WO2010149942A1 (en) 2009-06-25 2010-12-29 Institut Biophytis Composition for protection from the sun

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252865A (en) * 1962-12-17 1966-05-24 Hoffmann La Roche Stabilized fat-soluble vitamin compositions
US3252864A (en) * 1962-12-07 1966-05-24 Hoffmann La Roche Stable fat-soluble vitamin-containing compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252864A (en) * 1962-12-07 1966-05-24 Hoffmann La Roche Stable fat-soluble vitamin-containing compositions
US3252865A (en) * 1962-12-17 1966-05-24 Hoffmann La Roche Stabilized fat-soluble vitamin compositions

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
US4190594A (en) * 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4713398A (en) * 1985-08-30 1987-12-15 Microbio Resources, Inc. Naturally-derived carotene/oil composition
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
WO1991003571A1 (en) * 1989-08-30 1991-03-21 Applied Food Biotechnology, Inc. Production of zeaxanthin and zeaxanthin-containing compositions
US5308759A (en) * 1989-08-30 1994-05-03 Applied Food Biotechnology, Inc. Production of zeaxanthin and zeaxanthin-containing compositions
US5427783A (en) * 1989-08-30 1995-06-27 Applied Food Biotechnology, Inc. Zeaxanthin-containing compositions produced by flavobacterium multivorum
US5510551A (en) * 1991-04-12 1996-04-23 Humanetics Corporation Extraction of carotenoids from natural sources
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
WO1996019217A1 (en) * 1994-12-22 1996-06-27 Henkel Corporation Pharmaceutical compositions comprising lycopene
US6362221B1 (en) 1994-12-22 2002-03-26 Cognis Corporation Compositions containing natural lycopene and natural tocopherol
EP0759294A3 (en) * 1995-06-15 1999-12-01 Mutsunori Fujiwara Hypercholesterolemia therapeutic agent
EP0759294A2 (en) * 1995-06-15 1997-02-26 Mutsunori Fujiwara Hypercholesterolemia therapeutic agent
US5712311A (en) * 1995-06-16 1998-01-27 L'oreal Cosmetic or dermatological composition with controlled release of active principle containing a photoconvertible carotenoid
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
US6787147B1 (en) * 1998-10-23 2004-09-07 Norman Huner Solar radiation protection composition
US20030078304A1 (en) * 2000-03-27 2003-04-24 Tove Andersson Method of inhibiting the expression of inflammatory cytokines and chemokines
US7078040B2 (en) * 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
US6433025B1 (en) * 2000-04-13 2002-08-13 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US20030108598A1 (en) * 2000-10-27 2003-06-12 Garnett Kevin M. Zeaxanthin formulations for human ingestion
US7691406B2 (en) 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
US10420715B2 (en) 2001-11-14 2019-09-24 Lycored Ltd. Carotenoid composition and method for protecting skin
US20050053559A1 (en) * 2001-11-14 2005-03-10 Morris Zelkha Carotenoid composition and method for protecting skin
WO2003047528A3 (en) * 2001-12-04 2003-12-18 Pedro E Levy Supplements containing annatto extracts and carotenoids and methods for using the same
WO2003047528A2 (en) * 2001-12-04 2003-06-12 Levy Pedro E Supplements containing annatto extracts and carotenoids and methods for using the same
US20050106131A1 (en) * 2002-02-21 2005-05-19 Lionel Breton Photoprotective orally administrable composition for skin
US20070280999A1 (en) * 2002-02-21 2007-12-06 Nestec S.A. Orally administrable composition for the photoprotection of the skin
US10688139B2 (en) 2002-02-21 2020-06-23 Société des Produits Nestlé S.A. Orally administrable composition for the photoprotection of the skin
WO2003070260A1 (en) * 2002-02-21 2003-08-28 Societe Des Produits Nestle S.A. A photoprotective orally administrable composition for skin
US20090104169A1 (en) * 2002-02-21 2009-04-23 Nestec S. A. Pet food composition for skin photoprotection
US20050069505A1 (en) * 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US8715627B2 (en) 2002-10-28 2014-05-06 Zeavision Llc Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
US20040081628A1 (en) * 2002-10-28 2004-04-29 Gierhart Dennis L. Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US9682024B2 (en) 2002-10-28 2017-06-20 Zeavision, Llc Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
US9192587B2 (en) 2002-10-28 2015-11-24 Zeavision, Llc Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
US8481009B2 (en) 2002-10-28 2013-07-09 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US8501163B2 (en) 2002-10-28 2013-08-06 Zeavision Llc Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
US9980922B2 (en) 2002-12-23 2018-05-29 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
EP1643965A2 (en) * 2003-02-01 2006-04-12 ZeaVision, L.L.C. Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
EP1643965A4 (en) * 2003-02-01 2010-12-15 Zeavision L L C Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US10307384B2 (en) 2003-03-10 2019-06-04 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20050147648A1 (en) * 2003-03-10 2005-07-07 Gierhart Dennis L. Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US9474724B2 (en) 2003-03-10 2016-10-25 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US10842757B2 (en) 2003-03-10 2020-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US11045431B1 (en) 2003-03-10 2021-06-29 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients,for protecting eye health and treating eye disorders
US11173133B2 (en) 2003-03-10 2021-11-16 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US20050171212A1 (en) * 2003-11-17 2005-08-04 Gierhart Dennis L. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2010149942A1 (en) 2009-06-25 2010-12-29 Institut Biophytis Composition for protection from the sun

Similar Documents

Publication Publication Date Title
US3920834A (en) Light-screening compositions and method
US6433025B1 (en) Method for retarding and preventing sunburn by UV light
Kumari Vitiligo treated with topical clobetasol propionate
Jansen et al. Pathogenesis and treatment of acne in childhood
US6573299B1 (en) Method and compositions for treatment of the aging eye
US3920808A (en) Method of protecting human skin from actinic radiation
JP6125760B2 (en) Carotenoid compositions and methods for protecting the skin
AU2006305546A1 (en) Compositions for treatment of eye diseases
JP2000511923A (en) Compositions with sunburn and photoprotective activity and their cosmetic application
DK151850B (en) USE OF CANTHAXANTHIN AS A LIGHT FILTER SUBSTANCE IN LIGHT PROTECTION AGENTS
AU2002363613A1 (en) Carotenoid composition and method for protecting skin
AU772825B2 (en) Sunscreen agent for oral administration
RU2003122060A (en) CAROTINOIDS AS ANTIHYPERTENSIVE AGENTS
JPS61501030A (en) Pharmaceutical composition for the treatment or prevention of acne by topical application
EP1616556B1 (en) Compositions comprising gelatin-glycine and carotenoids
AU2019219081B2 (en) A tanning composition
CZ31798A3 (en) Cosmetic way of treating and prevention signs of skin ageing
US20050031557A1 (en) Oral administration of beta-carotene, lycopene and lutein for human skin protection
AU762968B2 (en) Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
JPH0791195B2 (en) Capsule for oral administration of active vitamin Ds
JPH06263647A (en) Inhibitor against lipoperoxide
Schalock ROSACEA AND PERIORAL (PERIORIFICIAL)